Clinical Trial

AMT-116 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-02-02; most recent amendment 2025-08-13.
Status change: Not Yet Recruiting → Recruiting 2023-07-24
Trial Details
NCT Number NCT05725291
Lead Sponsor Multitude Therapeutics Inc.
Conditions Advanced Solid Tumor
Enrollment 80 participants
Start Date 2023-07-25
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-17